Families Travel for Affordable Life-Saving Drug

In a move offering hope to many, a Bangladeshi pharmaceutical company has developed a generic version of a life-saving cystic fibrosis drug, Trikafta. This new medication, named Triko, is being sold at a fraction of the price charged by the U.S.-based manufacturer, Vertex Pharmaceuticals, whose original drug costs approximately $346,000 per year in the United States. Patients and their families, facing unaffordable treatment costs in their home countries, are traveling to Dhaka to acquire this significantly cheaper alternative.

The Bangladeshi company, Beximco Pharmaceuticals, is leveraging a loophole in global patent law, as Bangladesh is classified as a least-developed country exempt from certain World Trade Organization patent infringement laws. This allows them to reverse-engineer and produce generics of patented medications. This initiative has drawn patients from various nations, including South Africa, where the cost of the original drug was prohibitive.

While Vertex Pharmaceuticals states Trikafta is available in 75 countries through sales or donations, many patients remain underserved. Beximco's Triko provides a new pathway, costing $6,350 a year for children and double that for adults, still a substantial sum but life-changing for many. The company has previously produced affordable generics for treatments like hepatitis C and COVID-19 antivirals, demonstrating a commitment to accessible medication.

Families who have struggled to access or afford Trikafta are finding immense relief with Triko. For some, like Josua Lottering from South Africa, the drug has brought immediate improvements in breathing and overall well-being, allowing them to eat and experience life more fully. This development highlights the growing impact of generic drug production in addressing global health disparities.